Clinical Trial Search

Primary: Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm I — 19; 11; 11; 4 Months

Primary: Number of Participants With Pathological Response — 0; 4; 8; 3 Participants

Primary: Overall Survival (OS) — 11.96 Months

Primary: Grade 3 or Higher Toxicity Incidence on Step 1 — 65.8 percentage of participants

Primary: Reponse Rate at Time of Surgery by Tissue — 40 participants

Primary: Number of Participants With Objective Response Rate (ORR), of GSK1363089, Per- Response Evaluation Criteria in Solid Tumors (RECIST) Criteria Version 1.0 — 0; 0…

Primary: Overall Survival (OS) After Hyperthermic Intraperitoneal Chemotherapy — 30.2 Months

Primary: Clinical Response Rate of an Induction Regimen Consisting of Irinotecan, Cisplatin and Cetuximab — 40 percentage of paticipants

Primary: Significant Blood Test Findings Correlated With Gastric Neoplasms — 9.9; 6.5 score on a scale

Primary: Response Rate — 0 percentage of patients responding

Primary: Number of Participants With Accurate Diagnosis for Gastric Cancer — 27; 44 participants

Primary: Relapse-free Survival — 50.0; 60.2 percentage of participants

Primary: a) Number of Participants With High Pain Levels (Using the Visual Analog Scale) — 31; 3 Participants

Primary: Pathologic Complete Response (pCR) Rate — 7 Participants

Primary: Objective Response Rate (ORR) — 3.92 Participants (%)

Primary: Response Rate — 28.9; 26.1 percentage of participants

Primary: Overall Response Rate (ORR) — 39.1 percentage of participants

Primary: RR — 15 Participants

Primary: Relapse-free Survival Rate — 67.0; 64.9 percentage of participants

Primary: Percentage of Participants With Objective Response (Objective Response Rate) — 32.1; 67.9 percentage of responders

Primary: Progression-free Survival — 4.7; 5.1 months

Primary: Overall Survival — 13.4 month

Primary: Progression-free Survival Rate at 4-month (16 Weeks) — 18.4 percentage of participants

Primary: Overall Survival (OS) - Percentage of Participants With an Event — 62.8; 56.8 percentage of participants

Primary: Objective Response (Complete, Partial, Stable and Progression) — 0; 7; 22; 9 participants

Primary: Objective Best Tumor Response — 1; 15; 22; 24 participants

Primary: Percentage of Participants With Overall Response Rate (ORR) Based on Modified Response Evaluation Criteria in Solid Tumors (RECIST) — 15.4 percentage of participants

Primary: Percentage of Participants With Detectable Confocal Endoscopic Microscopy (CEM) w/Greater Sensitivity for Detection of Signet Ring Cells (SRC)Foci in Cadherin-1 (CDH1)…

Primary: Expected and Unexpected Provider Costs — 2264.1; 522; 1135.7; 846 HK$

Primary: The Difference in Cell DNA Damage, Based on Percent Positive Cells, Between Patients Treated With DFMO and Patients Treated With Placebo at 6 Months. — 5.07; 7.32…